| Autor: |
Platzbecker, U., Thiede, C., Füssel, M., Geissler, G., Illmer, T., Mohr, B., Hänel, M., Mahlberg, R., Krümpelmann, U., Weissinger, F., Schaich, M., Theuser, C., Ehninger, G., Bornhäuser, M. |
| Předmět: |
|
| Zdroj: |
Leukemia (08876924); Apr2006, Vol. 20 Issue 4, p707-714, 8p, 1 Diagram, 2 Charts, 3 Graphs |
| Abstrakt: |
There is substantial need to improve the outcome of patients with high-risk acute myeloid leukemia (AML). The clinical trial reported here investigated a new approach of up-front allogeneic hematopoietic stem cell transplantation (HSCT), provided a median of 40 days (range 22–74) after diagnosis, in twenty-six consecutive patients with newly-diagnosed high-risk AML characterized by poor-risk cytogenetics (n=19) or inadequate blast clearance by induction chemotherapy (IC, n=7). The median age was 49 years (range 17–68). During IC-induced aplasia after the 1st (n=11) or 2nd (n=15) cycle, patients received allogeneic peripheral blood stem cells (PBSC) from related (n=11) or unrelated (n=15) donors following a fludarabine-based reduced-intensity regimen. Seventeen patients were not in remission before HSCT with a median marrow blast count of 34% (range 6–70). All patients achieved rapid engraftment and went into remission with complete myeloid and lymphatic chimerism. Grades II to IV acute GvHD occurred in 14 (56%) and extensive chronic GvHD was documented in 8 (35%) patients. The probability of disease-free survival was 61% with only three patients relapsing 5, 6 and 7 months after transplantation, respectively. Up-front allogeneic HSCT as part of primary induction therapy seems to be an effective strategy in high-risk AML patients and warrants further investigation.Leukemia (2006) 20, 707–714. doi:10.1038/sj.leu.2404143; published online 16 February 2006 [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
